Therapeutic plasma exchange in China
One procedure, two reputations. In a hospital it is a first-line treatment with fifty years of evidence behind it; in a longevity clinic it is an idea with a great deal of promise and very little proof. Here is where the line falls, and which side of it we are on.
The short answer
Therapeutic plasma exchange — TPE, sometimes plasmapheresis, marketed lately as “blood cleaning” — takes your blood out through a line, separates the plasma from the cells, removes or filters that plasma, and returns the cells with a replacement fluid. In the Boao Lecheng pilot zone in Hainan it is delivered as double-filtration apheresis in the hospital’s day-treatment unit, a session taking an afternoon, and it sits on the non-cell side of the programme menu alongside functional infusion medicine, the mitochondrial and NAD+ course, hyperbaric oxygen and whole-body hyperthermia.
Two things are true at once and you need both. Plasma exchange is real, established, physician-supervised hospital medicine for a specific and quite short list of diseases. And plasma exchange as a longevity intervention in healthy people rests on one small human study, a handful of rodent experiments and a mechanism that is genuinely interesting. Those are different claims with different evidence behind them, and most of the marketing you will find online quietly borrows the credibility of the first to sell the second.
What the machine is actually doing
Blood is roughly 45% cells and 55% plasma. Plasma is water carrying everything dissolved and suspended in it: albumin, immunoglobulins, clotting factors, lipoproteins, hormones, cytokines, immune complexes, protein-bound drugs and whatever metabolic burden has accumulated there. Apheresis exploits the fact that these two fractions separate cleanly, by spinning the blood in a centrifuge or by passing it across a membrane with pores that cells cannot cross.
Conventional TPE discards the separated plasma entirely and replaces the lost volume, usually with human albumin in saline and occasionally with donor plasma where clotting factors must be restored. A standard session exchanges about one to one and a half plasma volumes, which removes something in the order of 60–70% of whatever was dissolved in there. Removal is not elimination: substances redistribute out of the tissues afterwards, which is why exchange is prescribed as a course on a schedule rather than as a single event.
It needs venous access good enough to sustain flow, an anticoagulant in the circuit — usually citrate — and a nurse or physician watching throughout. That is the honest shape of it: a supervised extracorporeal procedure in a clinical unit, not a spa treatment with a drip stand.
Double-filtration: the variant run here, and why it matters
Double-filtration plasmapheresis (DFPP) adds a second filter. The plasma separated at the first stage is passed through a membrane fine enough to hold back large molecules but let smaller ones through. Immunoglobulins, immune complexes, LDL and lipoprotein(a), and fibrinogen are retained and discarded; the smaller fraction, including most of your own albumin, is returned to you.
| What it changes | |
|---|---|
| Replacement fluid | Far less of it is needed, because your own albumin comes back. That removes most of the exposure to donor plasma and the allergic reactions that come with it. |
| Selectivity | Removal is by molecular size rather than wholesale. The large-molecule fraction — the one carrying immune complexes and atherogenic lipoproteins — is what goes. |
| Trade-off | The circuit is more complex, the session is not shorter, and fibrinogen depletion is if anything the more prominent effect. Selective is not the same as gentle. |
DFPP is used far more widely in Japan and China than in Europe or the United States, which is why it is unfamiliar to many Western travellers reading about it for the first time. That cuts both ways: a mature technique with a substantial East Asian clinical literature, and also the one most often described to foreign guests in language no hospital protocol would use.
Where plasma exchange is established medicine
The reference point is the American Society for Apheresis, whose guideline — the ninth edition, published in the Journal of Clinical Apheresis in 2023 — grades apheresis indications by category and strength of evidence across 91 disease fact sheets and 166 categorised indications, roughly twenty of which carry TPE as accepted first-line therapy.
The Category I list is instructive because of how specific it is: thrombotic thrombocytopenic purpura, Guillain-Barré syndrome, myasthenic crisis, chronic inflammatory demyelinating polyneuropathy, anti-GBM disease, acute attacks of neuromyelitis optica spectrum disorder, hyperviscosity in monoclonal gammopathies, fulminant Wilson disease. In each, plasma exchange works because there is a defined molecule to take out.
Where the longevity claim comes from
It comes from parabiosis, and it is more interesting than its marketing deserves. The classical experiments surgically joined the circulations of a young and an old mouse and reported improvement in the old animal’s tissue repair. The obvious reading — something rejuvenating transferred from young blood — turned out to be only half the story. The Conboy laboratory at Berkeley argued the dominant effect ran the other way: old blood carries inhibitory factors, and diluting them accounts for much of the benefit. Mehdipour and colleagues tested that directly in 2020 in Aging, exchanging old rodent plasma for a neutral saline-albumin solution with no young blood involved at all, and reported improvement across tissues from all three germ layers.
The human follow-up is a single small clinical study: Kiprov, Conboy and colleagues, GeroScience 2022, applying repeated plasma exchange to mostly older adults and reporting a shift toward a younger systemic proteome, reduced markers of cellular senescence and DNA damage, and an epigenetic-age reduction in the region of two to five years.
That sentence is usually quoted with everything that matters removed. The endpoints are surrogates — proteomic profiles and methylation clocks, not disease, function or survival. The sample is small. It has not been replicated at scale by an independent group. And an epigenetic clock is a measurement instrument whose relationship to how long or how well you live is itself an open research question.
The nearest thing to a large controlled trial in an age-related condition is AMBAR — Boada and colleagues, Alzheimer’s & Dementia, 2020: 347 patients with mild-to-moderate Alzheimer’s disease randomised to plasma exchange with albumin replacement or sham over fourteen months. It reported 52% less functional decline (ADCS-ADL, p = .03) and a non-significant trend on cognition (ADAS-Cog, p = .06); the moderate-disease subgroup did better on both, and the mild group showed no change at all. It is the most serious trial in this space and a genuine signal — and also a subgroup-dependent result in one disease, not yet confirmed by a second phase 3.
So: promising mechanism, one small human longevity study on surrogate endpoints, one substantial trial in a specific disease with a mixed result. Anyone selling more certainty than that is selling certainty, not treatment.
The risks nobody’s brochure lists
Plasma exchange is well tolerated in experienced hands, and registry series put adverse events in the low single-digit percentage of procedures, mostly mild. “Mostly mild” is not “none”, and the list is specific enough to ask about.
There is also a harm that is not clinical at all. The “blood washing” clinics that grew up around long COVID — apheresis sold privately across several countries at four- and five-figure sums, outside any trial and without published outcomes — were the subject of a BMJ investigation in 2022, and they are the cautionary case for this whole category. The procedure was real. The supervision was sometimes real. What was missing was any way to find out whether it worked.
What is actually delivered here
At Boao Lecheng, plasma exchange is run as double-filtration apheresis in the hospital’s day-treatment unit — a session takes an afternoon — and it is prescribed, like everything else on the island, after the screen rather than before it. The fasting panel, the imaging and the specialist reading come first; what is proposed afterwards is written from your results. What happens on a longevity retreat, day by day →
It sits on the infusion and blood side of the menu with 1+X functional infusion medicine, the mitochondrial and NAD+ protocols, whole-body immune hyperthermia and the oxygen suites. All of these are session-based: there is no cleanroom, no batch and no two-week manufacturing wait behind any of them. Mitochondrial and NAD+ therapy in China →
It is not one of the three regenerative programmes included in the four-day retreat, and it is not something we would propose to a guest whose panel gives no reason for it. The retreat itself is the assessment; the protocols are what the assessment may or may not point to. What a medical health retreat in Hainan includes →
Why this is not cell therapy, and what that changes
Cell and gene therapy in mainland China is governed by State Council Order No. 818, in force since 1 May 2026: medicine, for disease, in licensed institutions, against filed indications, with a hospital panel deciding candidacy. Order 818 and what the zone licenses →
Plasma exchange is not a cell product and does not travel on that route, so no diagnosis is required of you and nothing has to be manufactured — an autologous cell product takes roughly two weeks in a cleanroom, while an apheresis session can be scheduled the day the panel writes it.
Who it suits, and who should not bother
It suits someone whose screen turns up a reason for it — a lipid or lipoprotein(a) picture that will not move, an immunological finding, a specific circulating target the panel can name — and who wants the procedure supervised, sequenced against their own results and documented rather than bought as a package.
It does not suit someone who wants a number to quote afterwards, someone whose interest is general “detoxification” with no named target, or someone on anticoagulation or with a procedure imminent, for whom the coagulopathy window is a real constraint. And it is not the strongest thing on this island: if the assessment finds something treatable, the licensed programmes are the part that is genuinely hard to obtain elsewhere. Is stem cell therapy safe? →
What it costs
We do not publish prices for the treatment programmes. Plasma exchange is not inside the four-day retreat — that is offered from about $2,700 all-in, covering the precision screen, the specialist reading, the villa, the meals, the transfers, twelve months of follow-up and one of the three regenerative programmes. Comparable Alpine longevity programmes publish at roughly $39,000–115,000 for a week.
Because TPE is session-based, what it costs is driven by session count, replacement fluid and the monitoring around it rather than by a manufacturing batch — which is exactly why a figure that exists before anyone has read your results is a statement about the seller. Anything beyond the retreat’s inclusions is quoted by the hospital that would deliver it, in writing, before you commit. What a longevity program in China costs, and what is included →
Seven questions to ask any plasma exchange clinic
Frequently asked
What is therapeutic plasma exchange?
Therapeutic plasma exchange, or TPE, is an apheresis procedure. Blood is drawn continuously through a line, a centrifuge or a membrane filter separates the plasma from the red cells, platelets and white cells, the plasma is discarded or filtered, and the cells are returned to you with a replacement fluid — usually human albumin in saline, sometimes donor plasma. A session takes a few hours and clears roughly one to one and a half plasma volumes. It is the plasma that is the target: everything dissolved in it, including antibodies, immune complexes, lipids, inflammatory mediators and protein-bound toxins, leaves with it.
Is plasma exchange therapy available in China?
Yes. Therapeutic plasma exchange is standard hospital apheresis practice across Chinese tertiary hospitals, and it is one of the infusion and blood protocols run by the partner hospitals in the Boao Lecheng pilot zone in Hainan, where it is delivered as double-filtration apheresis in the day-treatment unit. Unlike licensed cell and gene therapy, it is a session-based procedure with no manufacturing run behind it and no filed-disease-indication restriction, so it is available to well guests as part of a retreat as well as to patients.
What is double-filtration plasmapheresis and how does it differ from ordinary plasma exchange?
Conventional TPE removes the whole plasma and throws it away, so the volume has to be replaced with albumin or donor plasma. Double-filtration plasmapheresis, or DFPP, passes the separated plasma through a second filter that fractionates it by molecular size: the large molecules — immunoglobulins, immune complexes, LDL and lipoprotein(a), fibrinogen — are removed, and the smaller ones including most of your own albumin are returned. The practical consequences are less dependence on replacement fluid, less albumin loss, and a more selective removal profile. It is the variant used most widely in Japan and China, and it is the one run at Boao Lecheng.
Does plasma exchange work for anti-ageing?
Not in the sense the word usually implies, and anyone who says otherwise is ahead of the evidence. The mechanism is serious: heterochronic blood-exchange experiments in rodents, and the neutral blood exchange work of Mehdipour and colleagues in 2020, support the idea that diluting the circulating proteome of an old animal improves tissue repair markers. In humans there is one small clinical study — Kiprov, Conboy and colleagues, GeroScience 2022 — reporting a shift toward a younger systemic proteome and an epigenetic-age reduction of roughly two to five years after repeated exchanges. It is small, the endpoints are surrogates rather than health outcomes, and it has not been replicated at scale. That is a reason the question is open, not an answer to it.
What are the side effects and risks of plasma exchange?
The common ones are citrate-related: the anticoagulant used in the circuit binds calcium, so perioral tingling, paraesthesia, cramps and nausea are frequent and are managed with calcium during the session. Hypotension during volume shifts is common. Less common and more serious are allergic or anaphylactoid reactions — markedly more likely with donor-plasma replacement than with albumin — vascular access complications, and a transient coagulopathy from fibrinogen depletion that matters if you are due surgery or a dental procedure. Repeated exchanges also deplete immunoglobulins, which has an infection implication over a course. Registry series put adverse events at a few percent of procedures, mostly mild. Plasma exchange also strips protein-bound drugs, so the timing of your own medication has to be planned around it.
Do I need a diagnosis to have plasma exchange in the pilot zone?
No. Plasma exchange is not a cell product, so it does not travel on the route that State Council Order No. 818 governs. Licensed cell and gene therapy in the zone is currently delivered for therapeutic purpose only — it proceeds where the assessment finds a treatable condition, or where you arrive holding a diagnosis or prescription from your own physician. The non-cell protocols, plasma exchange among them, carry no such restriction. You are still screened, and the hospital can still decline you on clinical grounds.
How much does plasma exchange in China cost?
We do not publish a price list for the treatment programmes, and plasma exchange is not one of the three regenerative programmes included in the four-day retreat, which is offered from about $2,700 all-in. Because TPE is session-based and has no manufacturing run behind it, what it costs tracks the number of sessions, the replacement fluid used and the monitoring around them rather than a batch — which is also why a figure quoted before anyone has read your results is telling you about the seller, not the protocol. Anything beyond the retreat's own inclusions is quoted in writing by the hospital that would deliver it, before you commit.
Write to us →Tell us where you’re starting from — a care manager replies within one working day.Or download the Retreat Dossier (PDF) → — itinerary, inclusions, programs, practicalities.